Role of SIRT3 in digestive system diseases and therapeutic prospects (Review).
The family of silent information regulators (sirtuins) constitutes a highly conserved protein family that exhibits two primary enzymatic activities : NAD‑dependent protein deacetylase activity and ade
APA
Li J, Liu Q, et al. (2026). Role of SIRT3 in digestive system diseases and therapeutic prospects (Review).. International journal of molecular medicine, 57(2). https://doi.org/10.3892/ijmm.2025.5719
MLA
Li J, et al.. "Role of SIRT3 in digestive system diseases and therapeutic prospects (Review).." International journal of molecular medicine, vol. 57, no. 2, 2026.
PMID
41456501
Abstract
The family of silent information regulators (sirtuins) constitutes a highly conserved protein family that exhibits two primary enzymatic activities : NAD‑dependent protein deacetylase activity and adenosine diphosphate‑ribose transferase activity. Sirtuin 3 (SIRT3), a member of the sirtuin family, is widely expressed in mitochondria‑rich tissues such as the brain, heart, liver and kidney, and functions primarily as a deacetylase. The deacetylations regulated by SIRT3 modulate various metabolic substances and processes within the mitochondrial matrix, playing a crucial role in maintaining normal digestive system function. Therefore, this review focuses on the role of SIRT3 in digestive system diseases to elucidate its function in pathogenic signaling pathways and explore the development of drug targets targeting SIRT3 and related disease pathways, offering new directions for improving the treatment of digestive system‑related diseases.
MeSH Terms
Humans; Digestive System Diseases; Sirtuin 3; Animals; Signal Transduction
같은 제1저자의 인용 많은 논문 (5)
- Ultrasound guided transabdominal botulinum toxin injection for refractory overactive bladder treatment.
- Short Nose Lengthening in Primary and Revision Rhinoplasty in Asians.
- Histopathological changes of fibrosis in human extra-ocular muscle caused by botulinum toxin A.
- Corrigendum to "Dual-energy CT radiomics for predicting neoadjuvant chemotherapy response in locally advanced gastric cancer: A dual-vendor validation study" [Eur. J. Surg. Oncol. 51 (2025) 110548].
- A case report of breast cancer recurrence with cystitis: the impact of immune checkpoint inhibitor therapy on the incidence of cystitis.